Possible presence of [3H]glutathione (GSH) binding sites in synaptic membranes from rat brain

Glutathione in the Nervous System as a Potential Therapeutic Target to Control the Development and Progression of Amyotrophic Lateral Sclerosis

Amyotrophic lateral sclerosis (ALS) is a rare neurological disorder that affects the motor neurons responsible for regulating muscle movement. However, the molecular pathogenic mechanisms of ALS remain poorly understood. A deficiency in the antioxidant tripeptide glutathione (GSH) in the nervous system appears to be involved in several neurodegenerative diseases characterized by the loss of neuronal cells. Impaired antioxidant defense systems, and the accumulation of oxidative damage due to increased dysfunction in GSH homeostasis are known to be involved in the development and progression of ALS. Aberrant GSH metabolism and redox status following oxidative damage are also associated with various cellular organelles, including the mitochondria and nucleus, and are crucial factors in neuronal toxicity induced by ALS. In this review, we provide an overview of the implications of imbalanced GSH homeostasis and its molecular characteristics in various experimental models of ALS.

Gclc deficiency in mouse CNS causes mitochondrial damage and neurodegeneration

Gamma glutamyl cysteine ligase (GCL) is the rate-limiting enzyme for intracellular glutathione (GSH) synthesis. The GSH concentration and GCL activity are declining with age in the central nervous system (CNS), and is accompanied by elevated reactive oxygen species (ROS). To study the biological effects of low GSH levels, we disrupted its synthesis both at birth by breeding a Gclc loxP mouse with a thy1-cre mouse (NEGSKO mouse) and at a later age by breeding with a CaMKII-ERT2-Cre (FIGSKO mouse). NEGSKO mice with deficiency of the Gclc in their entire CNS neuronal cells develop at 4 weeks: progressive motor neuron loss, gait problems, muscle denervation and atrophy, paralysis, and have diminished life expectancy. The observed neurodegeneration in Gclc deficiency is of more chronic rather than acute nature as demonstrated by Gclc targeted single-neuron labeling from the inducible Cre-mediated knockout (SLICK) mice. FIGSKO mice with inducible Gclc deficiency in the forebrain at 23 weeks after tamoxifen induction demonstrate profound brain atrophy, elevated astrogliosis and neurodegeneration, particularly in the hippocampus region. FIGSKO mice also develop cognitive abnormalities, i.e. learning impairment and nesting behaviors based on passive avoidance, T-Maze, and nesting behavior tests. Mechanistic studies show that impaired mitochondrial glutathione homeostasis and subsequent mitochondrial dysfunction are responsible for neuronal cell loss. This was confirmed by mitochondrial electron transporter chain activity analysis and transmission electron microscopy that demonstrate remarkable impairment of state 3 respiratory activity, impaired complex IV function, and mitochondrial swollen morphology in the hippocampus and cerebral cortex. These mouse genetic tools of oxidative stress open new insights into potential pharmacological control of apoptotic signaling pathways triggered by mitochondrial dysfunction.

Cardiovascular responses to l-glutamate microinjection into the NTS are abrogated by reduced glutathione

Redox imbalance in regions of the CNS controlling blood pressure is increasingly recognized as a leading factor for hypertension. Nucleus tractus solitarius (NTS) of the dorsomedial medulla is the main region receiving excitatory visceral sensory inputs that modulate autonomic efferent drive to the cardiovascular system. This study sought to determine the capacity of reduced glutathione, a major bioactive antioxidant, to modulate NTS-mediated control of cardiovascular function in unanaesthetized rats. Male Fischer 344 rats were used for microinjection experiments. Cardiovascular responses to l-glutamate were first used to verify accurate placement of injections into the dorsomedial region comprising the NTS. Next, responses to GSH or vehicle were recorded followed by responses to l-glutamate again at the same site. GSH microinjection increased mean arterial pressure (MAP) compared to vehicle and abrogated responses to subsequent injection of l-glutamate. These data indicate that GSH microinjection into the NTS affects blood pressure regulation by dorsomedial neuronal circuits and blunts l-glutamate driven excitation in this region. These findings raise the possibility that increased antioxidant actions of GSH in NTS could contribute to autonomic control dysfunctions of the cardiovascular system.

Targeting brain cells with glutathione-modulated nanoliposomes: in vitro and in vivo study

Background

The blood–brain barrier prevents many drug moieties from reaching the central nervous system. Therefore, glutathione-modulated nanoliposomes have been engineered to enhance the targeting of flucytosine to the brain.

Methods

Glutathione-modulated nanoliposomes were prepared by thin-film hydration technique and evaluated in the primary brain cells of rats. Lecithin, cholesterol, and span 65 were mixed at 1:1:1 molar ratio. The molar percentage of PEGylated glutathione varied from 0 mol% to 0.75 mol%. The cellular binding and the uptake of the targeted liposomes were both monitored by epifluorescent microscope and flow cytometry techniques. A biodistribution and a pharmacokinetic study of flucytosine and flucytosine-loaded glutathione–modulated liposomes was carried out to evaluate the in vivo brain-targeting efficiency.

Results

The size of glutathione-modulated nanoliposomes was <100 nm and the zeta potential was more than −65 mV. The cumulative release reached 70% for certain formulations. The cellular uptake increased as molar percent of glutathione increased to reach the maximum at 0.75 mol%. The uptake of the targeted liposomes by brain cells of the rats was three times greater than that of the nontargeted liposomes. An in vivo study showed that the relative efficiency was 2.632±0.089 and the concentration efficiency was 1.590±0.049, and also, the drug-targeting index was 3.670±0.824.

Conclusion

Overall, these results revealed that glutathione-PEGylated nanoliposomes enhance the effective delivery of flucytosine to brain and could become a promising new therapeutic option for the treatment of the brain infections.

Intracerebroventricular injection of glutathione and its derivative induces sedative and hypnotic effects under an acute stress in neonatal chicks

Glutathione-related enzymes glyoxalase 1 and glutathione reductase 1 regulates anxiety in mice. To clarify the central function of glutathione as a neurotransmitter in the stress reaction, the effect of intracerebroventricular (i.c.v.) injection of reduced (GSH) (0.5, 1, 2 micromol) and oxidized (GSSG) glutathione (0.25, 0.5, 1 micromol) were investigated under an isolation-induced stress in the neonatal chick. Both GSH and GSSG dose-dependently decreased distress vocalizations and induced sleep-like behavior in chicks under acute stressful conditions. However, which glutathione is actually responsible for inducing sleep was unclear since glutathione cycles between GSH and GSSG in which two tripeptides are linked by a disulfide bond. Therefore, the behavior of chicks was monitored following the i.c.v. injection of S-methylglutathione (SMG) (0.0625, 0.25, 1 micromol). SMG does not form a disulfide bond due to the methylation of the SH group of the cysteine moiety. SMG had similar effects as observed in GSH and GSSG. In conclusion, glutathione and its derivative have sedative and hypnotic effects, and might be effective in improving psychic stress such as anxiety.

Involvement of amino-acid side chains of membrane proteins in the binding of glutathione to pig cerebral cortical membranes

Glutathione (GSH), a general antioxidant and detoxifying compound, is the most abundant thiol-containing peptide in the central nervous system. It has been earlier shown to regulate the functions of glutamate receptors and to possess specific binding sites in both neurons and glial cells. The possible involvement of disulfide bonds, cysteinyl, arginyl, lysyl, glutamyl, and aspartyl residues in the binding of tritiated GSH to specific sites in pig cerebral cortical synaptic membranes was now studied after covalent modification of membrane proteins. Treatment of synaptic membranes with the thiol-modifying reagents 5,5'-dithio-bis(2-nitrobenzoate) (DTNB) and 4,4'-dithiodipyridine (DDP) dramatically enhanced the binding of [3H]GSH in a dose-dependent manner. Dithiothreitol (DTT) alone reduced the binding, but pretreatment of the membranes with DTT potentiated the enhancing effect of DTNB. On the other hand, when the modification with DTNB was followed by treatment with DTT, the enhancement by DTNB was completely reversed. N-ethylmaleimide, a thiol alkylating agent, and phenylisothiocyanate, a thiol- and amino-group modifying compound, reduced the binding, and their effects were additive. The guanidino-modifying agent phenylglyoxal reduced the binding but the carboxyl-modifying reagent 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide had no significant effect. The results indicate that cysteinyl side chains and disulfide bonds are essential in the binding of GSH to membrane proteins and that arginyl and lysyl side chains may also be directly involved in this process.

Consolidation of transient ionotropic glutamate signals through nuclear transcription factors in the brain

Long-lasting alterations of neuronal functions could involve mechanisms associated with consolidation of transient extracellular signals through modulation of de novo synthesis of particular functional proteins in the brain. In eukaryotes, protein de novo synthesis is mainly under the control at the level of gene transcription by transcription factors in the cell nucleus. Transcription factors are nuclear proteins with an ability to recognize particular core nucleotides at the upstream and/or downstream of target genes, and thereby to modulate the activity of RNA polymerase II that is responsible for the formation of mRNA from double stranded DNA. Gel retardation electrophoresis is widely employed for conventional detection of DNA binding activities of a variety of transcription factors with different protein motifs. Extracellular ionotropic glutamate (Glu) signals lead to rapid and selective potentiation of DNA binding of the nuclear transcription factor activator protein-1 (AP1) that is a homo- and heterodimeric complex between Jun and Fos family members, in addition to inducing expression of the corresponding proteins, in a manner unique to each Glu signal in murine hippocampus. Therefore, extracellular Glu signals may be differentially transduced into the nucleus to express AP1 with different assemblies between Jun and Fos family members, and thereby to modulate de novo synthesis of the individual target proteins at the level of gene transcription in the hippocampus. Such mechanisms may be operative on synaptic plasticity as well as delayed neuronal death through consolidation of alterations of a variety of cellular functions induced by transient extracellular signals in the brain.

Specific glutathione binding sites in pig cerebral cortical synaptic membranes

Glutathione (gamma-glutamylcysteinylglycine) is a neuromodulator at glutamate receptors, but may also act as a neurotransmitter at sites of its own. The Na+-independent binding of [3H]glutathione to pig cortical synaptic membranes was characterized here using glycine, cysteine analogs, dipeptides and glutathione derivatives, and ligands selective for known glutamate receptors. L-Glutamate, pyroglutamate, quinolinate, (S)-5-fluorowillardiine and 6-nitro-7-sulfamoylbenzo[f]quinoxaline-2,3-dione were weak inhibitors at concentrations of 0.5 or 1 mM. D-Glutamate, L- and D-aspartate, glutamine, quisqualate, kynurenate, other N-methyl-D-aspartate receptor ligands and non-N-methyl-D-aspartate receptor ligands failed to displace [3H]glutathione. Except for weak inhibition by D-serine (0.5 mM), glycine and other ligands of the glycine co-activatory site in the N-methyl-D-aspartate receptors had no displacing effect. Similarly, metabotropic glutamate group I, II and III receptor agonists and antagonists and compounds acting at the glutamate uptake sites were generally inactive. Glutathione, oxidized glutathione, S-nitrosoglutathione, gamma-L-glutamylcysteine, cysteinylglycine, cysteine, cysteamine and cystamine were the most potent displacers (IC50 values in the micromolar range), followed by dithiothreitol, glutathione sulfonate and the S-alkyl derivatives of glutathione (S-methyl-, -ethyl-, -propyl-, -butyl- and -pentylglutathione). L-Homocysteinate and aminomethanesulfonate exhibited a moderate efficacy. Thiokynurenate, a cysteine analog and an antagonist at the N-methyl-D-aspartate receptor glycine co-activatory site, was a potent activator of glutathione binding. At 1 mM, some dipeptides also slightly activated the binding, gamma-L-glutamylleucine and gamma-L-glutamyl-GABA being the most effective. The specific binding sites for glutathione in brain synaptic membranes are not identical to any known excitatory amino acid receptor. The cysteinyl moiety is crucial in the binding of glutathione. The oxidation or alkylation of the cysteine thiol group reduces the binding affinity. The strong activation by thiokynurenate may indicate that the glutathione receptor protein contains a modulatory site to which co-agonists may bind and allosterically activate glutathione binding. The novel population of specific binding sites of glutathione gives rise to the possibility that they may have profound effects on synaptic functions in the mammalian central nervous system. The glutathione binding sites may be an important, and for the most part unrecognized, component in signal transduction in the brain.

Glutathione and signal transduction in the mammalian CNS

The tripeptide glutathione (GSH) has been thoroughly investigated in relation to its role as antioxidant and free radical scavenger. In recent years, novel actions of GSH in the nervous system have also been described, suggesting that GSH may serve additionally both as a neuromodulator and as a neurotransmitter. In the present article, we describe our studies to explore further a potential role of GSH as neuromodulator/neurotransmitter. These studies have used a combination of methods, including radioligand binding, synaptic release and uptake assays, and electrophysiological recording. We report here the characteristics of GSH binding sites, the interrelationship of GSH with the NMDA receptor, and the effects of GSH on neural activity. Our results demonstrate that GSH binds via its gamma-glutamyl moiety to ionotropic glutamate receptors. At micromolar concentrations GSH displaces excitatory agonists, acting to halt their physiological actions on target neurons. At millimolar concentrations, GSH, acting through its free cysteinyl thiol group, modulates the redox site of NMDA receptors. As such modulation has been shown to increase NMDA receptor channel currents, this action may play a significant role in normal and abnormal synaptic activity. In addition, GSH in the nanomolar to micromolar range binds to at least two populations of binding sites that appear to be distinct from all known excitatory amino acid receptor subtypes. GSH bound to these sites is not displaceable by glutamatergic agonists or antagonists. These binding sites, which we believe to be distinct receptor populations, appear to recognize the cysteinyl moiety of the GSH molecule. Like NMDA receptors, the GSH binding sites possess a coagonist site(s) for allosteric modulation. Furthermore, they appear to be linked to sodium ionophores, an interpretation supported by field potential recordings in rat cerebral cortex that reveal a dose-dependent depolarization to applied GSH that is blocked by the absence of sodium but not by lowering calcium or by NMDA or (S)-2-amino-3-hydroxy-5-methyl-4-isoxazolepropionate antagonists. The present data support a reevaluation of the role of GSH in the nervous system in which GSH may be involved both directly and indirectly in synaptic transmission. A full accounting of the actions of GSH may lead to more comprehensive understanding of synaptic function in normal and disease states.

Increased glutathione levels in neurochemically identified fibre systems in the aged rat lumbar motor nuclei

The spinal cord motor nuclei have been the focus of a number of investigations exploring neurodegenerative mechanisms, e.g. excitotoxicity mediated by glutamate and oxidative stress. Here, high-resolution quantitative post-embedding immunocytochemistry with antibodies to oxidized and reduced glutathione (GSH), an ubiquitously expressed scavenger of free radicals, was used to examine if GSH synthesis is upregulated pre- and/or postsynaptically in the lumbar motor nuclei of aged (30 month old) rats. The purpose was, moreover, to resolve the extent of correlation between GSH expression, transmitter identity and degenerative changes. Tissue from young adult rats was co-processed for comparison. The quantitative immunogold analysis revealed an increase in GSH-immunoreactivity in both pre- and postsynaptic compartments in the lumbar motor nuclei of aged rats. Presynaptically, the enrichment of GSH-immunoreactivity was seen in axonal boutons of normal appearance, and was furthermore restricted to the extra-mitochondrial compartment. Postsynaptically, the aged rats disclosed, in comparison with young adults, higher values for GSH-immunoreactivity both over mitochondria (+49%) and cytoplasmic matrix (+130%). When analysing the transmitter identity of the bouton profiles, it turned out that close to 50% of all glutamate-immunoreactive boutons in the aged rats contained very high levels (> 40 gold particles/microm2) of GSH-immunoreactivity. Strong GSH-immunoreactivity was also a typical feature of a subset of axon terminal- and axon fibre-like profiles in the aged rat that showed signs of axon dystrophy and degeneration. When comparing with normally appearing axon fibre profiles located in close vicinity, the population of aberrant axons had higher average levels of glutamate-immunoreactivity (+93%), and lower average levels of glycine-immunoreactivity (-88%). No difference was seen regarding the levels of GABA. The results of this study lend support to the idea that aging in the spinal cord motor nuclei is associated with an increased oxidative stress and indicate that different transmitter systems are differentially affected by the degenerative process.

Sensitization by prolonged glutathione depletion of kainic acid to potentiate DNA binding of the nuclear transcription factor activator protein-1 in murine hippocampus

In four of four mice intracerebroventricularly injected with the inhibitor of glutathione synthesis L-buthionine-[S,R]-sulfoximine (BSO) 2 days before, an intraperitoneal injection of kainic acid (KA) invariably led to marked potentiation of DNA binding activity of the nuclear transcription factor activator protein-I (AP1) in the hippocampus at a dose which was ineffective in animals previously injected with vehicle alone. However, KA failed to potentiate binding in animals injected with BSO 1 day before. The intracerebroventricular injection of BSO induced marked and prolonged depletion of a total glutathione content in murine hippocampus for 1-2 days after administration. These results suggest that prolonged depletion of endogenous glutathione for a period longer than 1 day may lead to sensitization of KA signals to potentiate AP1 DNA binding in cell nuclei and thereby modulate de novo synthesis of particular proteins at the level of gene transcription in murine hippocampus.

Oxidized glutathione promotes sleep in rabbits

Glutatione is implicated in sleep regulation. There are circadian changes in brain glutathione levels, and nocturnal intracerebroventricular (i.c.v.) slow infusion of oxidized glutathione (GSSG) or reduced glutathione (GSH) promotes rapid-eye-movement sleep (REMS) and non-REMS (NREMS) in rats. In the present experiments, we tested the effects of GSSG on duration of sleep, NREMS intensity, and brain temperature in another species, rabbits. Male New Zealand rabbits were injected with isotonic NaCl on a baseline day and one dose of GSSG on the test day [0.15, 1.5, 15, and 150 microg/rabbit, i.c.v., or 1.5 or 15 mg/kg intravenously (i.v.)]. Electroencephalogram (EEG), motor activity, and brain temperature were recorded for 6 h. Injection of 15 microg GSSG i.c.v. significantly increased the time spent in NREMS in the first 3 h after the injection. Injection of 0.15, 1.5, and 150 microg i.s.v. GSSG, as well as systemic injections of GSSG did not affect NREMS. Intensity of NREMS as measured by EEG slow-wave activity during NREMS, and brain temperature were not affected by any of the treatments. These results are consistent with the hypothesis that glutathione may be a sleep-inducing factor in the brain.

Glutathione is an endogenous ligand of rat brain N-methyl-D-aspartate (NMDA) and 2-amino-3-hydroxy-5-methyl-4-isoxazolepropionate (AMPA) receptors

A study was made of the effects of reduced (GSH) and oxidized (GSSG) glutathione on the Na(+)-independent and N-methyl-D-aspartate (NMDA) displaceable bindings of glutamate, on the binding of kainate, 2-amino-3-hydroxy-5-methyl-4-isoxazolepropionate (AMPA), and ligand of the brain NMDA receptor-ionophore complex: glycine, dizocilpine (MK-801) and (+/-)-3-(2-carboxypiperazin-4-yl)propyl-1-phosphonate (CPP). GSH and GSSG strongly inhibited the binding of glutamate, CPP and AMPA, kainate and glycine binding being less affected. Both peptides enhanced the binding of dizocilpine in a time- and concentration-dependent manner. This activatory effect was not additive to that of saturating concentrations of glutamate or glutamate plus glycine. The activation of dizocilpine binding by GSH and GSSG was prevented by the competitive NMDA and glycine antagonists DL-2-amino-5-phosphonovalerate and 7-chlorokynurenate. GSH and GSSG may be endogenous ligands of AMPA and NMDA receptors, binding preferably to the glutamate recognition site via their gamma-glutamyl moieties. In addition to this, at millimolar concentrations they may regulate the redox state of the NMDA receptor-ionophore complex.

Evidence for generation of oxidative stress in brain by MPTP: in vitro and in vivo studies in mice

The role of oxidative stress in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-mediated neurotoxicity is as yet unclear and the evidence for generation of oxygen free radicals as a primary event in the neurotoxicity is yet to be demonstrated. The present study was undertaken to ascertain the potential role of oxidative damage, and the protective role, if any, of the antioxidant, glutathione (GSH), in MPTP-induced neurotoxicity. Exposure of sagittal slices of mouse brain to MPTP resulted in significant increases of reactive oxygen species (ROS) and malondialdehyde (MDA, the product of lipid peroxidation) and decreases in GSH content. Pretreatment of mouse brain slices, in vitro, with GSH or GSH isopropyl ester attenuated MPTP toxicity as assessed by the tissue activity of the mitochondrial enzyme, NADH-dehydrogenase (NADH-DH), and by leakage of the cytosolic enzyme, lactate dehydrogenase (LDH), from the slice into the medium. In vivo administration of MPTP (30 mg/kg body weight, s.c.), to mice resulted in significant lowering of GSH in the striatum and midbrain, 2 h after dosage; ROS levels in the striatum and midbrain increased after 4 and 8 h, respectively. In the striatum significant inhibition of rotenone-sensitive NADH ubiquinone-1 oxido-reductase (Complex 1) was observed transiently 1 h after MPTP administration. The enzyme activity recovered thereafter; significant inhibition of mitochondrial Complex I was observed in the striatum only 18 h after MPTP dose. In the midbrain, mitochondrial Complex I was inhibited only 18 h after MPTP dose; no change was observed at the early time points examined. Thus, the depletion of GSH and increased ROS formation preceded the inhibition of the mitochondrial enzyme in the midbrain. Evidence presented herein from both in vitro and in vivo studies support that MPTP exposure generates ROS resulting in oxidative stress.

Sleep as neuronal detoxification and restitution

The classical 'hypnotoxin theory' was followed by extensive search for an endogenous sleep substance. Brain tissues and body fluids of sleeping and sleep-deprived animals contained active sleep-inducing factors like the sleep-promoting substance (SPS). Uridine and oxidized glutathione (GSSG), two components of SPS, seem to regulate physiological sleep differentially. Uridine may facilitate the inhibitory neurotransmission at the synaptic level of the GABAA-uridine receptor complex. In contrast, GSSG may inhibit the excitatory neurotransmission at the synaptic level of the glutamate receptor. Thus, the two SPS components promote sleep by exerting a complementary action on the two major neurotransmitter systems in the brain that have mutually reciprocal functions. Further, among multidimensional functions of sleep, uridine may contribute to recover the activity of neurons, while glutathione may counteract excitotoxic events. Hence sleep at the behavioral level is a process of neuronal restitution and detoxification at the cellular level. Such a concept can be regarded as a modern version of the Ishimori-Piéron's hypnotoxin theory proposed early in this century.

Antisera to glutathione: characterization and immunocytochemical application to the rat cerebellum

Rabbits were immunized with reduced glutathione (gamma-glutamyl-cysteinyl-glycine) coupled to bovine serum albumin by glutaraldehyde or a mixture of glutaraldehyde and formaldehyde. The antisera that were formed were tested qualitatively, by screening them against more than 50 amino acids and peptide conjugates that had been immobilized on cellulose discs (spot test), and quantitatively, by immunogold analysis of test conjugates that had been embedded in an epoxy resin. It was shown that the antisera selectively recognized the reduced and oxidized forms of glutathione and that they did not exhibit any significant crossreactivity with glutamate, cysteine, glycine, gamma-glutamyl-cysteine or cysteinyl-glycine. Immunocytochemistry of Vibratome sections of rat cerebellum suggested that glutathione occurs in glial cells as well as in neurons. This was confirmed by electron microscopic, immunogold cytochemistry of tissue from rat cerebellum that had been freeze-substituted and embedded in Lowicryl under low temperature. Gold particles were concentrated over Golgi epithelial cells and perivascular glial processes, but also occurred over several types of neuronal profile including Purkinje and granule cell bodies, and mossy fibre terminals. At the subcellular level, glutathione-like immunoreactivity was found in the cytoplasmic matrix, mitochondria and nuclei. The immunolabelling intensity was strongly reduced in animals that had been pretreated with buthionine sulphoximine, which is known to depress the level of glutathione by inhibiting gamma-glutamyl-cysteine synthetase. The availability of antisera to glutathione is likely to further our understanding of the physiological and pathophysiological roles of this tripeptide.

Increased [35S]glutathione binding sites in spinal cords from patients with sporadic amyotrophic lateral sclerosis

Recent observations have suggested abnormalities in the gene for superoxide dismutase (SOD1) in patients with the familial form of amyotrophic lateral sclerosis (ALS). As SOD activity has secondary effects on glutathione (GSH), we have evaluated [35S]GSH binding in spinal cord sections from patients who died with sporadic ALS and control subjects. [35S]GSH binding sites were present in the grey matter of spinal cords in both the dorsal and ventral horns. ALS patients showed significantly increased [35S]GSH binding (+16%) in the dorsal and ventral grey horns compared to controls. Scatchard analysis of saturation binding data revealed that increased [35S]GSH binding was due to changes in the number rather than the affinity of GSH binding sites. These findings add support to a role for GSH in the mechanism loading to the pathogenesis of sporadic ALS.

Modulatory role of glutathione on mu-opioid, substance P/neurokinin-1, and kainic acid receptor binding sites

Reduced glutathione (L-gamma-glutamyl-L-cysteinylglycine; GSH) is an endogenous tripeptide involved in the formation and maintenance of protein thiol groups as well as in various detoxification reactions. Because multiple receptor types contain thiol groups or disulfide bridges, effects of GSH treatments on mu-opioid, neurokinin-1/substance P, and kainic acid receptor binding sites were investigated and compared with those produced by dithiothreitol (DTT), a potent synthetic reducing agent. GSH inhibited binding more potently than did DTT at all three receptor types in porcine striatal membrane homogenates as well as in CHAPS-solubilized preparations of the mu and neurokinin-1 sites. GSH-induced inhibitory effects were associated with decreases in maximal binding capacity (Bmax) without significant alteration in apparent affinity (KD). Cysteine, the functional moiety of GSH, mimicked GSH effects albeit with lower potencies, whereas oxidized glutathione had no effects at similar concentrations. In CHAPS-solubilized preparations, the combination of low concentrations of GSH and guanylylimidodiphosphate markedly decreased the Bmax values of the binding of [3H][D-Ala2,Gly-ol5]enkephalin and [3H]substance P. This GSH-mediated mechanism may be important to prevent cell overstimulation by accelerating receptor uncoupling, desensitization, and/or internalization. This is in keeping with purported roles of GSH related to the maintenance of cellular integrity.

Screening of thiol compounds: depolarization-induced release of glutathione and cysteine from rat brain slices

Superfusates from rat brain slices were screened for thiol compounds after derivatization with monobromobimane by reversed-phase HPLC. Only glutathione and cysteine were detected. The Ca(2+)-dependent release of these compounds from slices of different regions of rat brain was investigated, applying a highly sensitive and reproducible quantification method, based on reduction of superfusates with dithiothreitol, reaction of thiols with iodoacetic acid, precolumn derivatization with o-phthalaldehyde reagent solution, and analysis with reversed-phase HPLC. This methodology allowed determination of reduced and total thiols in aliquots of the same superfusates. Mostly reduced glutathione and cysteine were released upon K+ depolarization and the Ca2+ dependency suggests that they originate from a neuronal compartment. The GSH release was most prominent in the mesodiencephalon, cortex, hippocampus, and striatum and lowest in the pons-medulla and cerebellum. This underscores a physiologically significant role for glutathione in CNS neurotransmission.

Effects of exogenous factors on the cerebral glutathione in rodents

Since glutathione is thought to be involved in cerebral functions, changes in the glutathione level imply modulations of the neurotransmission in addition to all the known effects of GSH. It was investigated whether alterations of the cerebral glutathione can be induced by consumption of GSH, by inhibition or stimulation of the synthesis of GSH, or by an inhibition of the re-reduction of the oxidized glutathione. Aminophenazone, propyphenazone, acetaminophen, phenytoin, morphine and nitrofurantoin, known to deplete hepatic GSH, had no effects on cerebral GSH. Diethyl maleate (0.6 ml/kg) decreased the cerebral content of GSH and GSSG in adult rats as well as in fetuses. The depletion of the cerebral GSH caused by diethyl maleate treatment for 4 days was followed by an increase up to 125% and a subsequent return to the normal level after 1 week. In rats starved up to 71 h deficiency of exogenous amino acids caused only a minimal or no decrease in cerebral GSH. The specific inhibitor of the gamma-glutamylcysteine synthetase BSO only depleted GSH in the brain of young mice following the repeated s.c. administration of a high dose (890 mg/kg). After cobaltous chloride (20 mg/kg; twice a day for 2 or 4 days) the GSH level in the brain was unchanged. In vivo inhibition of the cerebral glutathione reductase was caused by ammonium metavanadate (12.5 mg/kg; three times a week for 6 weeks). Nitrofurantoin (150 mg/kg) had no effect. After lomustine (10 mg/kg) a minimal increase in glutathione reductase was found, but simultaneously also an increase in GSSG and of the ratio GSSG/total glutathione.

Neurochemical aspects of the N-methyl-D-aspartate receptor complex

The N-methyl-D-aspartic acid (NMDA)-sensitive subclass of brain excitatory amino acid receptors is supposed to be a receptor-ionophore complex consisting of at least 3 different major domains including an NMDA recognition site, glycine (Gly) recognition site and ion channel site. Biochemical labeling of the NMDA domain using [3H]L-glutamic acid (Glu) as a radioactive ligand often meets with several critical methodological pitfalls and artifacts that cause a serious misinterpretation of the results. Treatment of brain synaptic membranes with a low concentration of Triton X-100 induces a marked disclosure of [3H]Glu binding sensitive to displacement by NMDA with a concomitant removal of other several membranous constituents with relatively high affinity for the neuroactive amino acid. The NMDA site is also radiolabeled by the competitive antagonist (+/-)-3-(2-carboxypiperazin-4-yl)propyl-1-phosphonic acid that reveals possible heterogeneity of the site. The Gly domain is sensitive to D-serine and D-alanine but insensitive to strychnine, and this domain seems to be absolutely required for an opening of the NMDA channels by agonists. The ionophore domain is radiolabeled by a non-competitive type of NMDA antagonist that is only able to bind to the open but not closed channels. The binding of these allosteric antagonists is markedly potentiated by NMDA agonists in a manner sensitive to antagonism by isosteric antagonists in brain synaptic membranes and additionally enhanced by further inclusion of Gly agonists through the Gly domain. Furthermore, physiological and biochemical responses mediated by the NMDA receptor complex are invariably potentiated by several endogenous polyamines, suggesting a novel polyamine site within the complex. At any rate, activation of the NMDA receptor complex results in a marked influx of Ca2+ as well as Na+ ions, which subsequently induces numerous intracellular metabolic alterations that could be associated with neuronal plasticity or excitotoxicity. Therefore, any isosteric and allosteric antagonists would be of great benefit for the therapy and treatment of neurodegenerative disorders with a risk of impairing the acquisition and formation process of memories.

Temperature-independent binding of [3H](+-)-3-(2-carboxypiperazin-4-yl)propyl-1-phosphonic acid in brain synaptic membranes treated by Triton X-100

Specific binding of [3H](+-)-3-(2-carboxypiperazin-4-yl)propyl-1-phosphonic acid (CPP), a highly selective antagonist for N-methyl-D-aspartic acid (NMDA) receptors, was examined in brain synaptic membranes treated with Triton X-100 by using a filtration assay method. Elevation of incubation temperature from 2 to 30 degrees C markedly diminished the binding. The binding reached a plateau within 5 min after the initiation of incubation at 2 degrees C, while the time required to attain an equilibrium was 1 min at 30 degrees C. The binding at 2 degrees C was rapidly dissociated by the addition of an excess of unlabeled CPP, NMDA and L-glutamic acid (L-Glu). The binding was also saturable with increasing concentrations of the ligand and displaced by various amino acids structurally related to L-Glu in a stereospecific manner. Competitive but not noncompetitive antagonists for the NMDA receptors invariably inhibited the binding. However, the binding was not prominently affected by agonists for the other subclasses of the brain excitatory amino acid receptors. Both reduced and oxidized forms of glutathione significantly displaced the binding. Scatchard analysis revealed that Triton treatment increased the affinity and density of binding sites which consisted of a single component. Among some endogenous tryptophan metabolites, kynurenic, anthranilic and quinolinic acids inhibited the binding. These results suggest that a filtration assay method is also useful to detect the binding of NMDA receptors in the brain.

Strychnine-insensitive binding of [3H]glycine to synaptic membranes in rat brain, treated with Triton X-100

Binding of radiolabelled glycine, a putative inhibitory neurotransmitter in mammalian lower central structures, was examined by using the synaptic membranes of the brain of rat, treated with Triton X-100. This treatment with Triton markedly potentiated the binding of [3H]glycine detected at 2 degrees C and 30 degrees C. However, this binding was not affected by three different convulsants, strychnine, picrotoxin and bicuculline. The binding was saturable at 2 degrees C, with increasing concentrations of [3H]glycine up to 1 microM. Scatchard analysis revealed that the binding sites consisted of a single component with a Kd of 202 nM and a Bmax of 1.74 pmol/mg protein. The binding was inhibited, not only by various amino acids structurally related to glycine, including D- and L-serine and D-, L- and beta-alanine, but was also eliminated by some peptides containing glycine, such as gamma-D- and gamma-L-glutamylglycine, glycine methylester and N-methyl-glycine. In addition, the strychnine-insensitive binding of [3H]glycine was significantly abolished by numerous quinoxaline antagonists for excitatory amino acid receptors in the brain. These results suggest that synaptic membranes of brain, treated with Triton X-100, are useful to detect the strychnine-insensitive binding of [3H]glycine and superior to untreated membranes in terms of the freedom from the confounding effects of some endogenous amino acids.

Selective potentiation by L-cysteine of apparent binding activity of [3H]glutathione in synaptic membranes of rat brain

Significant apparent binding activity of [3H]glutathione was detected in synaptic membranous preparations of the rat brain. In vitro addition of sucrose (50-1000 mM) and Triton X-100 (0.02-0.1%) significantly diminished the apparent binding activity, whereas pretreatment of the membranes with Triton X-100 (0.01-0.4%) did not affect the activity. A slight but statistically significant reduction of the apparent binding activity was induced by the in vitro addition (1 mM) of two constituent amino acids, L-glutamic acid and glycine. In contrast, another constituent amino acid, L-cysteine, potently enhanced the binding activity at a concentration higher than 0.1 mM. No prominent alteration of the activity occurred following the inclusion of structurally-related amino acids, dithiothreitol, dithioerythritol and numerous other amino acids. Scatchard analysis revealed that the apparent binding consisted of two independent separate components with Kd values of 0.76 and 11.0 microM, and Bmax values of 4.00 and 27.0 pmol/mg protein respectively. In vitro addition of 1 mM L-cysteine resulted in a single component with a Kd of 8.5 microM and a Bmax of 105 pmol/mg protein. Pretreatment of the membranes with 1 mM L-cysteine potentiated the apparent binding, with a further addition of L-cysteine having no effect. The retina had the highest activity followed by the hypothalamus, striatum, spinal cord, midbrain, hippocampus, medulla-pons, cerebellum and cerebral cortex, which occurred independently of the incubation temperature. In peripheral organs examined, the pituitary possessed higher activity than the retina, with progressively lower activities in the adrenal, liver, spleen, skeletal muscle and heart. No significant activity was detected in the kidney. Addition of 1 mM L-cysteine significantly potentiated the activities at 30 degrees, but not at 2 degrees, in the hippocampus and cerebral cortex without affecting those in other central structures. In contrast, a profound inhibition of the activity was induced by the addition of L-cysteine in the pituitary, adrenal, intestinal mucosa, skeletal muscle and retina independently of the temperature. These results suggest that L-cysteine may selectively potentiate the apparent binding activity of [3H]glutathione in particular regions of the brain, while eliminating that in the peripheral excitable tissues.

A glycine site associated with N-methyl-D-aspartic acid receptors: characterization and identification of a new class of antagonists

Membranes from rat telencephalon contain a single class of strychnine-insensitive glycine sites. That these sites are associated with N-methyl-D-aspartic acid (NMDA) receptors is indicated by the observations that [3H]glycine binding is selectively modulated by NMDA receptor ligands and, conversely, that several amino acids interacting with the glycine sites increase [3H]N-[1-(2-thienyl)cyclohexyl]piperidine ([3H]TCP) binding to the phencyclidine site of the NMDA receptor. The endogenous compound kynurenate and several related quinoline and quinoxaline derivatives inhibit glycine binding with affinities that are much higher than their affinities for glutamate binding sites. In contrast to glycine, kynurenate-type compounds inhibit [3H]TCP binding and thus are suggested to form a novel class of antagonists of the NMDA receptor acting through the glycine site. These results suggest the existence of a dual and opposite modulation of NMDA receptors by endogenous ligands.

Brain leukotriene C4 binding sites are S-alkylglutathione binding sites

Leukotriene C4 binding to mouse brain membranes was readily displaced by S-alkylglutathione derivatives, with the affinity of the test compound increasing as the alkyl chain length increases. S-decylglutathione was as potent as leukotriene C4. These data suggest that brain membrane leukotriene C4 binding sites are S-alkylglutathione binding sites, possibly microsomal glutathione transferase.

Temperature-dependent and -independent apparent binding activities of [3H]glutathione in brain synaptic membranes

An apparent binding activity of [3H]glutathione was examined by using synaptic membrane preparations of the rat brain. The activity was found to be more than two times as high at 30 degrees C as that found at 2 degrees C. At 2 degrees C, the apparent binding sites consisted of a single component with a Kd of 0.77 microM and a Bmax of 5.60 pmol/mg protein. In contrast, two independent separate sites with Kds of 0.56 and 12.6 microM and Bmaxs of 2.50 and 28.5 pmol/mg protein were observed at 30 degrees C. In vitro addition of Triton X-100 significantly inhibited the apparent binding activities detected at both temperatures, whereas pretreatment of the membranes with the detergent did not significantly affect both binding activities. Among 3 constituent amino acids of glutathione, L-cysteine induced a selective and irreversible potentiation of the apparent activities, which occurred independently of the incubation temperature. Scatchard analysis revealed that L-cysteine drastically increased the number of the low affinity sites without significantly altering their affinity. Apparent binding activities determined at both incubation temperatures were unevenly distributed in the central and peripheral structures. Distribution profile of the temperature-dependent activities was found to be closely related to that of the basal binding activity of [3H]L-glutamic acid, a putative central excitatory neurotransmitter. These results suggest that brain synaptic membranes may indeed contain specific binding sites of [3H]glutathione which have an interaction with the glutamate binding sites. Possible presence of two distinctly different apparent binding sites of [3H]glutathione, such as temperature-independent high affinity sites and temperature-dependent low affinity sites, is also suggested.